Exactly. So many unknowns......the cash could have taken Kevetrin through the final testing? It could have paid lawyer fees for the term sheet BP deal, could have produced brilacidin, could have reformulated B for IBD, or eczema. So many unknowns to be detailed soon........imo
""These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis." What's up with that?"
The quote you referenced looked like a piece of boilerplate to me.
It looks to me like IPIX is not really focussed on getting Prurisol out of hock while worrying more about maintaining cash flow for salaries. I bet that playing the role of pawn shop is something that the CRO never considered going into the trial.
Regarding the amount owed to the CRO, I remember 2.2 million from a filing a while back. There is no way I would ever even consider a partial payment...so unless P is out of hock completely my guess is that the amount owed is still the same.
News 
Market Data 
Discover 
